Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide

Fig. 1

Protocol for initiation and monitoring of everolimus therapy. *≤1.2 m2 = 2.5 mg once daily, 1.3–2.1 m2 = 5 mg once daily, ≥2.2 m2 = 7.5 mg once daily; †In the event of bleeding, temporary cessation of everolimus may be required for embolisation; everolimus may be restarted following healing if needed to control AML growth. AML angiomyolipoma, BSA body surface area, GFR glomerular filtration rate, GP general practitioner, SEGA subependymal giant astrocytoma

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172